CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that new preclinical data from its Duchenne muscular dystrophy (DMD) programs, including its lead gene transfer candidate, SGT-001, will be presented at the 21^st Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) held May 16-19, 2018 in Chicago.

Oral Presentations:

• AAV Micro-Dystrophin Therapy Ameliorates Muscular Dystrophy in Young Adult Duchenne Muscular Dystrophy Dogs for Up to Thirty Months Following Injection
  Abstract Number: 8
  Date/Time: Wednesday, May 16^th at 10:45 a.m. CT

• Identification of Novel AAV Capsids for Skeletal Muscle Gene Transfer By In Vivo Selection in Humanized Mice
  Abstract Number: 355
  Date/Time: Thursday, May 17^th at 4:30 p.m. CT

Poster Presentations:

• Assessing Anti-Dystrophin T-Cell Responses by Elispot Following AAV9-Microdystrophin Gene Therapy in Dogs
  Abstract Number: 219
  Date/Time: Wednesday, May 16^th at 5:30 p.m. CT

• In Vivo Comparison of the Biological Potency of rAAV9-Microdystrophin Made by Transient Transfection and a Scalable Herpesvirus System 
  Abstract Number: 626
  Date/Time: Thursday, May 17^th at 5:15 p.m. CT

• In Silico Platform for the Design and Generation of Novel Muscle Promoters: In Vitro Validation 
  Abstract Number: 869
  Date/Time: Friday, May 18^th at 5:45 p.m. CT

• Preclinical Evaluation of SGT-001 Microdystrophin Gene Transfer for Duchenne Muscular Dystrophy
  Abstract Number: 854
  Date/Time: Friday, May 18^th at 5:45 p.m. CT

• Complementary Techniques to Evaluate Microdystrophin Expression in Duchenne Muscular Dystrophy Gene Therapy Studies
  Abstract Number: 868
  Date/Time: Friday, May 18^th at 5:45 p.m. CT

About Solid Biosciences
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. Solid’s lead clinical candidate for DMD is a novel adeno-associated viral (AAV) vector-mediated microdystrophin gene transfer called SGT-001. The Phase I/II clinical trial for SGT-001, IGNITE DMD, is currently on clinical hold.  For more information, please visit www.solidbio.com.

Contact:
Solid Biosciences
Kate Niazi-Sai
+1 617-337-4680
media@solidbio.com 
investors@solidbio.com